Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Hepatitis C is the most common reason for liver transplantation in the United States and affects nearly 4 million Americans. Treatments for hepatitis C are available but are poorly tolerated and are not always effective. Morbidity and mortality from hepatitis C are related to the development and progression of hepatic fibrosis to cirrhosis and end stage liver disease. Efforts to block progression of liver disease would thus result in prevention of morbidity and mortality as well as costs incurred by the health system in the care of these conditions.
Scar tissue in the liver is secreted by a type of cell, called the stellate cell, in an activated state. This cell carries a receptor for angiotensin, a hormone, when activated. If this receptor is blocked, the cell becomes inactive and does not participate in scar tissue formation. Thus, we hypothesize that using a drug such as candesartan, which blocks angiotensin receptors, should result in less scar tissue formation in the livers of patients with hepatitis C.
Sex
Ages
Volunteers
Inclusion criteria
- Adults, age 21 and older
- Patients with viral hepatitis C that are not on interferon based therapy.
- Detectable viral load
- Baseline biopsy within six months or willing to undergo biopsy prior to drug initiation
- At least grade 2 inflammation on biopsy, fibrosis of stage 1 or higher
- Willing to undergo biopsy at the end of treatment
- No interferon for at least 6 months prior to or after initial biopsy for study
Exclusion criteria
- Renal impairment defined by a serum creatinine of >1.8
- Congestive heart failure
- Hepatocellular cancer
- Concurrent treatment with pentoxyfylline, steroids, interferon alpha or interferon gamma.
- Active psychosis (affective disorders without loss of reality testing acceptable)
- Active IV drug use
- Prior liver transplant
- Pregnancy
- Decompensated cirrhosis as defined by the presence of ascites, hepatic encephalopathy or coagulopathy with an INR>1.4
- HIV seropositivity
- Hypotension defined by a baseline systolic blood pressure of less than 90mm of mercury
- Contraindication to ARB use or allergy to medication
- Treatment with potassium sparing diuretics
Trial design
Primary purpose
Allocation
Interventional model
Masking
0 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal